September 4, 2015 at 9:33 pm #9240SeekingParticipant
First, thank you for all you do for this forum. I am hoping you can pls help with some questions on GHSV2 F to M transmission.
1. The general guideline for F to M GHSV2 xmission with oral suppressives and condoms is 1%. However, I have read numerous studies, such as the article below, where transmission rate is much less, more on the order of 0.4 to 0.5%. Is the lower value more accurate? if so, why is 1% the most frequently reported?
2. Could you please comment on the transmission rate you would estimate for oral suppressives plus the new Vivagel condoms? I am having a friend send some to me, so this is not a hypothetical question. I don’t believe there is data on large study groups, so I am just seeking your expert opinion.
3. If a person has GHSV2, what is the likelihood of contracting GHSV1 or OHSV1?
4. I understand that Westover Heights was involved in Phase 2 clinical trials for GEN 003. The web seems to have gone quiet on GEN 003 progress since May. Could you please share any update on GEN 003? Do you know when Phase 3 will begin?
September 5, 2015 at 4:09 am #9253Terri WarrenKeymaster
as you may have noticed, I am an author on the paper you cited. The rate of transmission in this particular study is lower than the rate we have seen in other studies. As an investigator on that study, I know that we really pushed people to be very aware of every little symptom that they might have of an outbreak being present or coming and avoid sex completely during that time. That doesn’t happen in the real world and it hasn’t happened to that degree in previous studies. I think the estimate of 1-2% with condoms and suppression is more accurate.
I am aware of the Vivagel condoms but have not seen an particular date on herpes transmission related to these new condoms. Theoretically, transmission would be less but since there are no studies yet, I cannot comment with any certainty about this, sorry.
In a study looking a pregnant women, the risk of acquiring HSV 1 subsequent to having HSV 2 was about 1 in 55,000.
As an investigator on the Gen 003 study, I am not at liberty to discuss details of results at this time. However, I would expect more about the trial to be released in the near future. Suffice to say, I think this is a very hopeful product.
You must register to ask your own question or be logged in to reply to this question.